ArticleProceedings of the National Academy of Sciences of the United States of America2025

EVOLVE platform, a trispecific T cell engager with integrated CD2 costimulation, for the treatment of solid and hematologic tumors.

Oksana A Sergeeva et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.